RYE BROOK, N.Y.--(BUSINESS WIRE)--SCHOTT, the international technology group and inventor of specialty glass, was among the winners of the Pharma Innovation Award for its SCHOTT TOPPAC® freeze prefillable polymer syringes. Pharma Manufacturing bestowed the honor for SCHOTT TOPPAC® freeze’s trailblazing solution to protecting deep-cold medications at temperatures approaching -100°C.

RYE BROOK，N.Y.-（商业线）-国际技术集团SCHOTT和特种玻璃发明家，因其SCHOTTTOPPAC®冷冻预充式聚合物注射器而获得制药创新奖。制药公司授予SchottToppac®freeze开拓性解决方案荣誉，以在接近-100°C的温度下保护深度冷药物。

The innovation highlights the impact of SCHOTT’s R&D team. The company invests 4% of its revenue into R&D activities to promote sustainable growth, and those efforts have spurred 3,500 worldwide patents..

这项创新突出了肖特研发团队的影响。该公司将4%的收入投入研发活动，以促进可持续增长，这些努力刺激了3500项全球专利。。

SCHOTT TOPPAC® freeze was introduced to the market in May 2023 to support the increasing number of medications that require frozen conditions to remain stable throughout the supply chain, from filling to administration. The syringes are made of cyclic olefin copolymer, are break-resistant, biologically inert, and feature advanced barrier properties to ensure drug stability..

SCHOTTTOPPAC®freeze于2023年5月上市，以支持越来越多的需要冷冻条件保持整个供应链稳定的药物，从填充到管理。注射器由环烯烃共聚物制成，具有抗断裂性，生物惰性，并具有先进的阻隔性能，以确保药物稳定性。。

“Winning the Pharma Innovation Award is an important accolade for our syringe that is changing the drug development pipeline in its first year,” said Patrick Gallagher, Vice President and Head of Polymer Solutions at SCHOTT Pharma. “The success of SCHOTT TOPPAC® freeze highlights our commitment to evolving the pharmaceutical industry, offering unparalleled safety and stability for the next generation of medications, which require precise temperature controls.”.

SCHOTT Pharma公司副总裁兼聚合物解决方案负责人Patrick Gallagher说：“获得制药创新奖是我们第一年正在改变药物开发流程的注射器的重要荣誉。“SCHOTTTOPPAC®freeze的成功凸显了我们对发展制药行业的承诺，为下一代需要精确温度控制的药物提供了无与伦比的安全性和稳定性。”。

Quickly, SCHOTT TOPPAC® freeze has had a big impact on the market. Two industry-leading pharmaceutical manufacturers have selected this syringe for their entire mRNA vaccine pipelines. This innovation, and quick demand for it, made the product worthy of one of the 13 awards bestowed by Pharma Manufacturing, which cites the awards are “a tribute to those who listen to the needs of the market and their customers, and a result, have distinguished themselves as leaders in pharma equipment and technology.”.

很快，SCHOTTOPPAC®freeze对市场产生了巨大影响。两家行业领先的制药商已经选择这种注射器用于他们的整个mRNA疫苗管道。这项创新和对其的快速需求使该产品成为制药制造业颁发的13项奖项之一，该奖项引用了这些奖项“向那些倾听市场及其客户需求的人致敬，结果，已经将自己视为制药设备和技术的领导者“。

Every minute, more than 25,000 patients safely receive an injection stored in one of SCHOTT’s primary packaging products. SCHOTT TOPPAC® freeze is another example of how SCHOTT puts patients first by making drug delivery safe, easy, and real.

每分钟，超过25000名患者安全地接受储存在SCHOTT主要包装产品之一中的注射剂。SchottToppac®freeze是SCHOTT如何通过使药物输送安全，简便和真实而将患者置于首位的另一个例子。

Pioneering – responsibly – together.

开拓-负责任-共同努力。

These attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years.

这些属性将SCHOTT定性为基于特种玻璃的高科技材料制造商。创始人奥托·肖特（Otto Schott）被认为是其发明者，并成为整个行业的先驱。始终以开拓性的精神和激情开辟新的市场和应用-这就是肖特130多年来#玻璃爱好者的动力。

Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2021, its 17,300 employees generated sales of 2.5 billion euros.

该公司代表34个国家，是高科技行业的高技能合作伙伴：医疗保健，家用电器和生活，消费电子，半导体和数据通信，光学，工业和能源，汽车，天文和航空航天。在2021财年，其17300名员工的销售额为25亿欧元。

SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030..

SCHOTT AG由卡尔蔡司基金会拥有，卡尔蔡司基金会是德国最古老的基金会之一。它利用集团的股息来促进科学。作为一家基础公司，肖特对员工，社会和环境负有深深的责任。目标是到2030年成为一家气候中立的公司。。